Key result
Micronized fenofibrate increased HDL-C levels by 13.3% from baseline compared with 5.3% for atorvastatin over 12 weeks.
Why the study?
Does micronized fenofibrate improve HDL-C levels compared to atorvastatin in nondiabetic dyslipidaemic patients with low HDL-C?
RCT (n=181)
open-label
randomized
Yes
Does micronized fenofibrate improve HDL-C levels compared to atorvastatin in nondiabetic dyslipidaemic patients with low HDL-C?
Micronized fenofibrate is more effective than low-dose atorvastatin at raising HDL-C levels in nondiabetic dyslipidemic patients.
Answers are grounded in this paper and cite their sources.
Fenofibrate raises HDL-C more effectively than atorvastatin in low-HDL dyslipidemia; extends RCT evidence on fibrate-statin lipid differences.
Després J‐P, Lemieux I, Salomon H, Delaval D (CHUL Research Center, Ste‐Foy, Québec, Laval Hospital Research Center, Ste‐Foy, Québec, Canada and Laboratoires Fournier, Garches, France). Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial. J Intern Med 2002; 251: 490–499. Background. Studies have suggested that raising low levels of high‐density lipoprotein cholesterol (HDL‐C) may be an important target for the prevention of coronary heart disease. Objective. To compare the ability of micronized fenofibrate and atorvastatin to increase plasma HDL‐C levels. Design. Multicentre, randomized open‐label study. Settings. The study was conducted in 19 centres across the UK and Canada. Subjects. One hundred and eighty‐one patients were randomized and the full analysis set included 165 nondiabetic patients with low HDL‐C (women <46 mg dL −1 , i.e. 1.2 mmol L −1 and men <43 mg dL −1 , i.e. 1.1 mmol L −1 ): 86 patients in the atorvastatin group and 79 patients in the micronized fenofibrate group. Interventions. Micronized fenofibrate (200 mg day −1 , 87 patients) or atorvastatin (10 mg day −1 , 94 patients) for a period of 12 weeks. Main outcome measures. Percent change in HDL‐C levels. Results. After 12 weeks of treatment, the mean percent change from baseline in HDL‐C was significantly higher in the micronized fenofibrate group (13.3%) compared with the atorvastatin group (5.3%, P =0.0003). The magnitude of such relative change was inversely related to the baseline HDL‐C levels only in the micronized fenofibrate group. Furthermore, in the fenofibrate treatment group, 50.9% of the patients (29 of 57 patients) with a baseline HDL‐C <40 mg dL −1 achieved a plasma HDL‐C level above 40 mg dL −1 after 12 weeks of treatment versus 27.9% of the patients (19 of 68 patients) in the atorvastatin group ( P =0.01). Conclusions. On the basis of (1) the greater impact of fenofibrate than atorvastatin on HDL‐C levels and (2) the greater proportion of dyslipidemic patients achieving HDL‐C levels above 40 mg dL −1 with fenofibrate than atorvastatin, it is suggested that micronized fenofibrate should be considered as a good therapeutic option to treat dyslipidemic patients with low HDL‐C and moderately elevated LDL‐C concentrations.
No takes yet. Share an insight, caveat, or question.
Després et al. (2002) conducted an RCT in Dyslipidaemia with low HDL-cholesterol (n=181). Micronized fenofibrate vs. Atorvastatin (10 mg/day) was evaluated on Percent change in HDL-C levels (p=0.0003). Micronized fenofibrate increased HDL-C levels by 13.3% from baseline compared with 5.3% for atorvastatin over 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: